Life Sciences & Healthcare Innovation Hub

Our innovation hub for life sciences and healthcare is a demonstration of Cooley’s enduring commitment to the industry. It serves as a centralized point from which to access the insights and unparalleled experience of leading legal thinkers from across the firm and around the world.

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

In a subdued year for global M&A, dealmaking in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. While the year saw an overall decline in M&A activity (down 17% from 2022), total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022.

How to Prepare for a Successful JPM Conference

The Cooley team discussed how to prepare for attending the JPM Healthcare Conference 2024 – including current industry trends and strategies for successful meetings with investors and partners. Attendees heard about how to make the most of your time at JPM from these trusted life sciences company advisers.

Watch now

Cooley Advises Lantheus on Concurrent PIPE Investment, Partnering Transaction, Asset Sale With Perspective Therapeutics

Cooley advised Lantheus Holdings, a publicly traded radiopharmaceutical-focused company, on a concurrent private investment in public equity (PIPE) transaction, partnering transaction and asset sale with Perspective Therapeutics.

January 9, 2024

Gracell Biotechnologies to be Acquired by AstraZeneca for up to Approximately $1.2 Billion

Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.

December 26, 2023

RayzeBio Signs Approximately $4.1 Billion Acquisition Agreement With Bristol Myers Squibb

Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.

December 26, 2023

Carmot Therapeutics Enters Definitive Merger Agreement With Roche

Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement pursuant to which Roche will acquire Carmot.

December 3, 2023